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Abstract
Background: Infantile spasms represent a serious epileptic syndrome that occurs in the early infantile age. ACTH
and Vigabatrin are actively investigated drugs in its treatment. This study describes the comparison of their efficacy
in a large series of patients with infantile spasms from Pakistan.
Methods: All patients with infantile spasms who presented to Aga Khan University Hospital, Karachi, Pakistan from
January, 2006 to April, 2008 were included in this study. Inclusion criteria were clinical symptoms of infantile
spasms, hypsarrythmia or modified hyparrythmia on electroencephalography, at least six months of follow-up
period and receipt of any of the two drugs mentioned above. The type of drug distribution was random according
to the availability, cost and ease of administration.
Results: Fifty six cases fulfilled the inclusion criteria. 62.5% were males. Mean age at onset of seizures was 5 ± 1.4
months. Fifty two (92.8%) patients demonstrated hypsarrythmia on electroencephalography. 64.3% cases were
identified as symptomatic while 19.6% were cryptogenic and 16.1% were idiopathic. Eighteen patients received
ACTH while 38 patients received Vigabatrin as first line therapy. Initial response to first line therapy was similar
(50% for ACTH and 55.3% for Vigabatrin). Overall, the symptomatic and idiopathic groups responded better to
Vigabatrin. The relapse rate was higher for ACTH as compared to Vigabatrin (55.5% vs. 33.3%) when considering
the first line therapy. Four patients evolved to Lennox-Gastaut variant; all of these patients had initially received
Vigabatrin and then ACTH.
Conclusion: Vigabatrin and ACTH showed no significant difference in the initial treatment of infantile spasms.
However, patients receiving ACTH were 1.2 times more likely to relapse as compared to the patients receiving
Vigabatrin when considering monotherapy. We suggest that Vigabatrin should be the initial drug of choice in
patients presenting with infantile spasms. However, larger studies from developing countries are required to
validate the therapeutic trends observed in this study.
Background
Infantile spasms represent a unique and age-specific epi-
lepsy disorder usually presenting in early infancy. If left
untreated, infantile spasms are associated with devastat-
ing neurological results. This severe epilepsy syndrome
is often considered an age-dependent expression of a
damaged brain [1].
The incidence of infantile spasms ranges from 0.25 -
0.6 per 1000 live births [2]. Electroencephalography
(EEG) characteristically demonstrates the hypsarrythmic
pattern. In addition, there is neurodevelopment regres-
sion [3]. Infantile spasm may be seen either alone or in
the constellation of West Syndrome. West syndromee
consists of the triad of infantile spasms, an interictal
EEG pattern (hypsarrhythmia or similar pattern), and
mental retardation. The key features to diagnosing
infantile spasms are patient history, age, characteristic
semiology of seizures, and distinctive EEG pattern [3].
These seizures typically present with a triad of light-
ning (involving the entire body), nodding (convulsions
of the throat and neck flexor muscles) and Salaam or
jackknife attacks (rapid bending of the head and torso
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arms) [1,4]. Infantile spasms are distinct from myoclonic
and tonic seizures. They are characterized by a contrac-
tion phase followed by a more tonic phase. The contrac-
tion phase may be a flexor spasm, extensor spasm, or a
combination of both and these could be symmetrical or
asymmetrical.
The frequent onset of infantile spasms in infancy sug-
gests that an immature central nervous system may be
important in its pathogenesis. The brain-adrenal axis
may also be involved. It is proposed that the effect of
different stressors in the immature brain produces an
abnormally excessive secretion of corticotropin-releasing
hormone (CRH), causing spasms. The clinical response
to adrenocorticotropic hormone (ACTH) and glucocor-
ticoids can be therefore be explained by the suppression
of CRH production [1].
The treatment of infantile spasms has been both a
conundrum and a challenge for the pediatric neurologist
as the entity appears to be resistant to many conven-
tional antiepileptic drugs. Agents that have been
employed in the treatment of infantile spasms include
benzodiazepams (especially nitrazepam), sodium valpro-
ate, vigabatrin (VGB), corticosteroids, ACTH, a keto-
genic diet, vitamin B6, intravenous gammaglobulin, a
benzodiazepam-carbamazepine cocktail, topiramate and
zonisamide [2,5].
Currently ACTH and vigabatrin are the actively inves-
tigated drugs with some evidence of efficacy in the treat-
ment of infantile spasms. However, there is little
consensus with regards to the definitive dose, efficacy or
duration of treatment of these agents in comparison to
each other [3]. Studies on experience with ACTH and
Vigabatrin from Pakistan and neighboring regions are
lacking. To date, there has been only one study from
Pakistan reporting the use of ACTH and prednisolone
[6]. There has been no study exploring the efficacy of
Vigabatrin in Pakistan. Therefore, this study was under-
taken to provide an important perspective on the treat-
ment of infantile spasms in the setting of a developing
country like Pakistan.
Methods
Study setting
The Aga Khan University Hospital (AKUH) is a tertiary
level teaching facility in the private sector in Karachi,
Pakistan. It has approximately 550 beds and provides
services to over 38,000 hospitalized patients and to over
500,000 outpatients annually [7]. Patients belonging to
all socioeconomic classes and from all over Karachi as
well as Pakistan visit to AKUH for treatment.
Study design
This study included 56 patients with infantile spasms
who presented to AKUH Consulting Clinic from
January, 2006 to April, 2008. Patient records were
reviewed and data was collected on structured profor-
mas especially prepared for this purpose.
Inclusion and exclusion criteria
Inclusion criteria included the following:
1. Clinical symptomatology of infantile spasms as eli-
cited by thorough physical examination and detailed
history
2. Accompanying EEG findings at initial EEG (hypsar-
rythmia or similar pattern on EEG with almost continu-
ous high voltage multifocal spike and wave discharge
and a disorganized/chaotic background)
3. At least six months of follow-up from the time of
initial diagnosis
4. Receipt of any of the two drugs mentioned above.
The type of drug administration was according to the
availability, cost and ease of administration.
Exclusion criteria used for this study were:
1. All children who were diagnosed to have tuberous
sclerosis were excluded since there is enough evidence
in literature of the advantage of Vigabatrin over steroids
in cases of infantile spasms with tuberous sclerosis.
2. Children who had already received any of the inves-
tigational drugs prior to their first encounter were also
excluded.
Working definitions
a. Response to therapy
Cases were considered as free from infantile spasms
either on the basis of clinical resolution of spasms or on
the basis of both clinical resolution of spasms and EEG
resolution of hypsarrythmia. A follow-up EEG couldn’t
be performed in all cases unfortunately due to financial
constraints cited by some parents. Partial response was
considered when the number of spasms was reduced by
at least ≥ 50% as compared to the baseline spasms at
initial presentation before the administration of any
drug. Patients were categorized as having no response
when there was no change in the number of spasms
even after a period of 6 weeks of adequate therapy.
b. Categories based on etiology
All cases were grouped into three categories. Those
cases in which infantile spasms occurred without any
identifiable cause, other neurological signs or symptoms
were considered as idiopathic. Patients who were sus-
pected of being symptomatic but for whom an underly-
ing structural or biochemical cause could not be
identified were classified as cryptogenic. Cases were con-
sidered as symptomatic when the infantile spasms
resulted from an identifiable cause and often where neu-
rologic features or unequivocal developmental delay pre-
ceded the onset of symptoms [8].
c. Dosages of medications
The starting dose of Vigabatr i nv a r i e df r o m1 2 . 5t o2 5
mg/kg/day in all the cases while the maximum dosage
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mg/kg/day. Increments were done every 3-5 days
depending on the tolerance of the patient to the drugs
administered. We must mention here that some chil-
dren became extremely lethargic and drowsy after
receipt of the medication; therefore the increments were
considerably slower in such children depending on their
clinical state. The maximum dosage of Vigabtrin that
was given to all cases depended on the response
observed.
For ACTH, the typical dosage was 40 International
Units (IU). However, in 2 children the dosages were
increased to a maximum of 80 units as their initial
response was considerably slower.
The children who showed a partial or no response to
the initial therapy after the maintenance doses of either
of the two medications for adequate time duration of 6
weeks were then put on a second drug. For example,
patients who were initially on Vigabatrin but failed to
show adequate response were put on ACTH. Similarly,
patients who were initially on ACTH but failed to show
adequate response were put on Vigabatrin. Patients who
showed response to the initial drug were maintained on
that therapeutic agent.
Data management and statistical analysis
The data was coded, entered and analyzed using Win-
dows SPSS version 16.0. In descriptive analysis, the
mean and standard deviations of the continuous vari-
ables and percentages of categorical variables were com-
puted. Associations were assessed using chi-square test
and Fisher’s exact test where appropriate. A p-value of <
0.05 was considered statistically significant, unless other-
wise specified. Variables with a significant p-value were
further subjected to multiple logistic regression analysis
to ascertain independent predictors of infantile spasm
free final outcome of treatment.
Ethical considerations
Being a retrospective study, the study protocol was
granted exemption from review as per guidelines of the
Ethical Review Committee (ERC) of the Department of
Pediatrics at Aga Khan University Hospital (AKUH),
Karachi. Informed consent was not needed owing to the
anonymous presentation of the patient data as per
guidelines of the ERC at AKUH.
Results
Fifty six children with infantile spasms were adminis-
tered either Vigabatrin or ACTH from 2006-2008. Apart
from these 56 patients, an additional two patients had
been given prednisolone as initial treatment for infantile
spasms. Although they showed complete resolution of
the infantile spasms, they were not included as part of
primary analysis due to insufficient numbers.
Clinical profile of patients
a. Baseline characteristics
The baseline characteristics of our sample are presented
in Table 1. The majority of the patients were male (35/
56, 62.5%). Twelve patients (21.4%) were small for gesta-
t i o n a la g ew i t hab i r t hw e i g h to fl e s st h a n2 . 5k g .A
family history of abortions and stillbirths was present in
3 patients (5.3%). A history of neonatal deaths in the
family was found in 4 cases (7.1%); however, the defini-
t i v ec a u s eo fd e a t hw a sn o tk n o w n .T h r e ep a t i e n t s
(5.3%) had a family member with mental retardation
and developmental delay. A family history of infantile
spasms was not present in any child. Antenatally,
mothers of 3 patients had a history of oligohydramnios
during gestation, 2 had a history of typhoid fever (blood
culture proven) in the first trimester, and 2 had a his-
tory of chorioamnionitis (clinical diagnosis) in the third
trimester. Two mothers also had a history of self-resol-
ving heaving bleeding in the first trimester. On presen-
tation 37/56 (66%) children had a fronto-occipital
circumference (FOC) less than 5
th centile. Four children
(7.1%) had brachycephaly on examination. All the
patients received an initial EEG. Fifty two (92.8%)
patients exhibited the classic hypsarrythmic pattern
while a similar pattern such as modified hypsarrythmia
was less commonly seen (7.2%). Of the 58 cases of
infantile spasms, forty two (75%) patients had not
received any prior anti-epileptic medications. The
remaining had been treated as non-specific seizure dis-
order before presenting to our hospital.
b. Etiology of infantile spasms
In our patient population, 36 (64.3%) of the cases of
infantile spasms were symptomatic while 11 (19.6%)
were cryptogenic and the remaining 9 cases were idio-
pathic (16.1%). The criteria used for classifying the cases
into symptomatic, cryptogenic and idiopathic types have
been mentioned in detail in the Methods section above.
Among the symptomatic cases, cerebral palsy secondary
to birth asphyxia was identified as the leading cause of
infantile spasms (Table 2). It was seen that almost 51.8%
(29/56) patients had a history of delayed cry at birth. As
per parental recall, the mean time for cry after birth was
7.5 ± 3.5 minutes. APGAR scores were not available in
most of the cases since the deliveries since the deliveries
had been performed outside our hospital.
Treatment and outcomes
a. Initial therapy of infantile spasms
All patients were given one medication at any given
time. Out of 56 patients, 18 patients (32.1%) received
ACTH while 38 patients (67.9%) received Vigabatrin as
initial therapy. The results of initial therapy are pre-
sented in Table 3. Initially, 9 out of 18 (50%) patients
completely responded to ACTH monotherapy while 21
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abatrin monotherapy initially.
b. Switch to second drug
As mentioned above, 50% and 44.7% patients initially on
ACTH and Vigabatrin therapy didn’t show adequate
response to therapy even after 6 weeks duration. These
were patients who showed either partial or no response
to the initial therapy. They were then put on a second
and different drug. Patients initially on ACTH were now
put on Vigabatrin and vice versa. The response of
patients to the second drug is shown in table 4.
c. Relapse
Even among patients who had shown complete resolu-
tion of seizures after therapy, some experienced relapse.
Fifty percent patients initially put on ACTH showed full
response. However, 5 out of these 9 patients (55.6%)
relapsed. Similarly, 21 patients had shown full response
to Vigabatrin initially. However, 7 out of these 21
patients (33.3%) relapsed. The relapse rate was higher
for ACTH as compared to Vigabatrin (55.5% against
33.3%) when considering the initial monotherapy.
The average time for relapse and complete cessation
of seizures also yielded interesting findings. It was
observed that the patients started on ACTH had earlier
relapses and delayed recovery (both clinically and based
on EEG findings), as opposed to those started on Viga-
batrin therapy. These time durations were 2 weeks for
the former and 2 months for the later. Those who were
switched to Vigabatrin after prior ACTH therapy
relapsed after 6 months on average as opposed to those
who were switched to ACTH therapy after prior Vigaba-
trin therapy, who relapsed after an average time of 2
months. (Table 5) Patients receiving ACTH were 1.2
times more likely to relapse as compared to the patients
receiving Vigabatrin when considering monotherapy.
d. Final outcome of patients
At the time of last follow-up, the cumulative outcome
was based either on EEG findings, and/or clinical signs
and seizure activity. (Table 5) Only four of the patients
initially on ACTH and 14 of the patients initially on
Vigabatrin remained seizure free at last follow-up and
had not experienced any relapse. Among those who
were started on the second drug after incomplete or no
response to the first drug, 93% of those on ACTH and
73% of those on Vigabatrin therapy continued to have
seizures. It was observed that 4 patients out of the 24
Table 1 Baseline characteristics of patients presenting with infantile spasms
Characteristics of patients with infantile spasms n = 56 (%)
Age of onset of seizures in months (Mean ± SD) 5 ± 1.4
Age at diagnosis of infantile spasms in months (Mean ± SD) 6.5 ± 2.3
Lag interval between onset and diagnosis in months (Mean ± SD) 1.4 ± 1.3
Gender (male) 35 (62.5%)
Consanguinity of parents 19 (33.9%)
Seizures per day at onset (Mean ± SD) 62 ± 5.1
Clusters per day at onset (Mean ± SD) 21 ± 4.2
Type of spasms
-Flexion 23 (41.1%)
-Extension 6 (10.7%)
-Mixed 15 (26.8%)
History of neonatal seizures 15 (26.8%)
History of stay in neonatal intensive care unit 14 (25%)
History of premature birth (< 37 weeks gestation) 14 (25%)
History of neonatal sepsis/meningitis 10 (17.8%)
History of developmental delay prior to onset of symptoms 41 (73.2%)
Table 2 Etiology of Symptomatic Infantile Spasms
Etiology of symptomatic cases of infantile spasms % (n = 36)
Birth asphyxia 69.4
Complication of pre-maturity 11.1
Post maturity (> 41 weeks gestation) 2.8
Aicardi Syndrome 2.8
Bilirubin encephalopathy (kernicterus) 2.8
Inborn error of metabolism ^ 5.5
Post meningitic sequalae 2.8
^ Urea cycle defect and Glutaric Acid deficiency were identified
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evolved to Lennox-Gastaut variant.
The association of the outcome at the last follow-up
was significant for the type of treatment received (p <
0.001), the etiology of infantile spasms (p < 0.001) and
the age at diagnosis of infantile spasms (p = 0.04). The
association of final outcome with age at onset seizures
was not significant (p = 0.869). For outcome at last fol-
low-up in terms of clinical and electroencephalographic
resolution of seizures, the following variables were sub-
jected to multiple logistic regression analysis: type of
treatment received, etiology of infantile spasms and age
at diagnosis. (Table 6) It was seen that response to first
line treatment, etiology other than symptomatic and
younger age at diagnosis are factors associated with
resolution of seizures.
e. Association of response to first line therapy with etiology
Considering the seizure outcome with respect to the
etiology, it was seen that 30% of all the patients in the
symptomatic group responded to monotherapy. Sixty
percent of this response was due to Vigabatrin while
3 4 %w a sd u et oA C T H .I nt h ec r y p t o g e n i cg r o u p ,3 6 %
patients responded to first line therapy. Distribution of
this response to first line therapy was 55% and 45% due
to Vigabatrin and ACTH respectively. In the idiopathic
group, almost 50% patients responded to first line ther-
apy. Vigabatrin accounted for all the responsive cases of
idiopathic group with regards to first line therapy.
f. Side effects of therapy
Comparing the side effect profile of the drugs, 6 patients
developed ACTH induced hypertension while 1 patient
developed Vigabatrin induced rash. One patient devel-
oped visual field defects secondary to Vigabatrin. How-
ever, many patients did not get a complete and detailed
eye examination done (including visually evoked poten-
tials and other studies) after being put on Vigabatrin
therapy due to non-availability of retinograms at our
institution.
g. Mortality
A total of 4 patients expired in this study; 2 were receiv-
ing vigabatrin at the time of death and their death was
attributed to aspiration pneumonia. The remaining 2
were on ACTH therapy and their death was attributed
to septicemia. All 4 cases were of symptomatic category
of infantile spasms.
Discussion
Infantile spasms were first described 160 yeas ago in a
letter that Dr West wrote to Lancet [9]. Since then
atleast 30 drugs have been investigated in the treatment
of infantile spasms, but hitherto, no definitive universal
standard exists for the treatment of infantile spasms.
Our study provides a developing world perspective on
the treatment of infantile spasms with particular refer-
ence to two drugs: Vigabatrin and ACTH. First line
therapy consisted of either ACTH or Vigabatrin in this
study. A second drug was started if the patients showed
partial or no response to one of the first line agents. At
any given time in the study, patients were put on not
more than one drug.
Birth asphyxia
Cerebral palsy secondary to birth asphyxia/hypoxic
ischemic encephalopathy was identified as the leading
cause of infantile spasms in our study, contributing to
almost 70% of the symptomatic cases. The diagnosis
was primarily based on history, neurological examina-
tion and brain imaging. The spectrum of underlying
etiologies in our study was quite similar to other studies.
In a large study, one-third of symptomatic patients had
birth related etiology [10]. In another study, hypoxic
ischemic encephalopathy was the commonest underlying
etiology [11]. According to data from the World Health
Organization, 4 - 9 million babies develop birth asphyxia
per year and of these, more than 1 million die and
roughly the same number develop neurological sequelae
[12]. Data from Pakistan has shown that it is one of the
leading causes for admission in a neonatal unit [13]. An
analysis of neonatal mortality and morbidity in Pakistan
has shown that most causes of neonatal morbidity in
Pakistan are preventable [14]. In a study conducted in
Pakistan, it was reported that lack of antenatal care in
mothers, delivery by unskilled birth attendants either at
home or a private health facility and prolonged labour
were significant risk factors for asphyxial insult at birth
[15,16]. Similarly, another study from Pakistan has
reported the association between lack of antenatal care,
poor nutritional status of mother and antepartum
hemorrhage with higher incidence of birth asphyxia
Table 3 Response of patients to initial therapy
Patient Response to Initial Therapy
(p = 0.696)
ACTH
n = 18 (%)
Vigabatrin
n = 38 (%)
-Complete cessation 9 (50) 21 (55.3)
-Partial response 6 (33.3) 10 (26.3)
-No response 3 (16.7) 7 (18.4)
Table 4 Response of patients to second drug that was
administered after 6 weeks in case of partial or no
response to first drug
Patient Response to Second Drug
(p = 0. 334)
ACTH ^
n = 17 (%)
Vigabatrin ^^
n = 9 (%)
-Complete cessation 5 (29.4) 2 (22.2)
-Partial response 5 (29.4) 5 (55.6)
-No response 7 (41.2) 2 (22.2)
^ Patients who had initially received Vigabatrin and shown partial or no
response to it
^^ Patients who had initially received ACTH and shown partial or no response
to it.
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unhealthy baseline maternal status as well as the poor
perinatal services offered in maternity homes, commu-
nities or hospitals [18]. In order to ameliorate the situa-
tion, increased coverage of the population by high
quality health services and skilled birth attendants is
imperative [19,20]. Evidence based and cost-effective
resuscitation strategies for neonates should be imple-
mented [21]. Improvements in proximal risk factors
such as female nutrition and prompt treatment as well
as prevention of infections should be the long term
goals of any policy geared towards improving maternal
and child health [17,21]. Similarly, improvement in
maternal education should be made a priority in both
urban and rural settings.
Therapeutic parameters
No statistically significant difference was observed
between the response rates (based on clinical observa-
tion and resolution on EEG when available) of patients
put on either ACTH or Vigabatrin therapy initially.
Responses to both the firsta n dt h es e c o n dd r u gw e r e
also almost similar, as obvious from the p-values derived
from chi-square or fisher’se x a c tt e s t i n g .However, tak-
ing the final outcome at the time of last follow-up into
account, it was seen that overall employment of mono-
therapy prognosticated better remission rates as com-
pared to patients who received a second drug as add-on
therapy. It was observed that the majority of the patients
who responded to treatment did so within the first few
weeks of being put on therapy. However, a full 6 weeks
of therapy was allowed in our study before switching to
the second drug.
The United Kingdom infantile spasms study compar-
ing vigabatrin with prednisolone or tetracosactide at 14
days was a multicentred randomized controlled trial
where the primary outcome was cessation of spasms at
day 13 and 14 [22]. According to the study, there was
more likelihood of cessation of spasms at day 14 in
Table 5 Final outcome at last follow-up
Therapy Seizure free till last
follow-up
Continued to have
seizures
Ave. relapse
time
Ave. recovery
time ^
Evolved to Lenox Gestaut
variant*
ACTH monotherapy
(n = 4) ^^
4 0 2 wks 2 months 0
Vigabatrin
monotherapy
(n = 14) ^^
14 0 2 months 1 month 0
ACTH followed by
Vigabatrin
(n = 14)
1 13 6 months 3 months 0
Vigabatrin followed by
ACTH
(n = 24)
2 18 2 months 6 months 4
^ Average time to complete recovery, if occurred
^^ Remained on monotherapy till the last follow-up and didn’t receive any second drug
* Evolution by 2 years
Table 6 Multiple logistic regression analysis showing predictors for final outcome of infantile spasms in terms of
resolution of seizures
Variables Resolution of Seizures
Adjusted OR *
(EEG and/or clinical)
95% CI **
Type of therapy (p < 0.001)
Receipt of second drug 1 -
ACTH monotherapy 4.2 0.6 - 6.8
Vigabatrin monotherapy 4.6 1.1 - 7.2
Etiology (p < 0.001)
Symptomatic 1 -
Cryptogenic 1.2 0.4 - 2.1
Idiopathic 4.4 1.6 - 6.9
Age at Diagnosis (p = 0.04)
> 12 months 1 -
6 - 12 months 1.2 0.8 - 1.5
< 6 months 1.3 0.6 - 2.1
* OR = Odds Ratio
** CI = Confidence Interval
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batrin. We didn’t observe similar results in our study.
Our period of treatment extended well beyond the 14
days parameter used in this study.
Even though younger age at onset has been associated
with a worse prognosis [9], but the results in our study
were inconsistent with this finding, where younger age
at diagnosis appeared to portend better chances of reso-
lution of infantile spasms. We believe that it is possible
that earlier diagnosis at a younger age led to earlier
administration of therapy which may have led to
improved outcomes.
When compared in terms of complete cessation of sei-
zures, both ACTH and Vigabatrin monotherapy as well
as add-on therapy showed average cessation rates ran-
ging between 20% and 50%. The results for Vigabatrin
are consistent with a class I randomized placebo-con-
trolled trial, which reported 35% response rate [23]. In
another large study, 21% to 44% patients responded to
Vigabatrin therapy [24]. Our results for ACTH are not
in agreement with a meta-analysis that showed a cessa-
tion rate ranging from 54% to 100% [25]. Several other
studies also report similar results [26,27]. One reason
for this inconsistency could be that the aforestated stu-
dies have used higher starting doses for ACTH, with 75
IU being the most common dose, as opposed to our
study, where the starting dose for 40 IU in almost all
cases. This can be further substantiated by two studies
that report that ACTH was effective at higher doses,
based both on response rate and plasma hormone data
[6,28-30].
Overall prognosis in our study was poor. After the
onset of spasms, 52/56 (92.8%) children showed devel-
opmental delay while only 4 children (7.2%) showed
normal developmental milestones. Most of the reports
from other countries also report poor outcome in infan-
tile spasms [27].
Considering the final seizure free outcome, etiology
and treatment used, it was seen that idiopathic group
and symptomatic groups responded well to Vigabatrin
as compared to ACTH. These results are consistent
with earlier performed studies. In one retrospective
study, it was seen that symptomatic children with devel-
opmental brain lesions responded at a rate of 83% to
vigabatrin versus 63% for ACTH. Cryptogenic spasms
responded at a similar rate to both drugs as was seen in
our study [31].
With regards to the side-effect profile, Vigabatrin was
better than ACTH; with only two patients experiencing
the adverse effects, as opposed to ACTH, where six
patients reported ACTH-induced hypertension. A pre-
vious study has reported arterial hypertension in 11 out
of 162 children (6.8%) on ACTH therapy. Mortality in
this study has been stated as 4.9%. The other mentioned
side effects included infections (being the most com-
mon), followed by marked electrolyte disturbances (10
patients), osteoporosis (2 patients), and hypokalaemic
alkalosis (2 patients) [32]. Septicemia was the cause of
death in both of our patients on ACTH therapy as men-
tioned above. Vigevano and Cilio have reported hormo-
nal treatments to have greater adverse effects and thus a
higher potential to induce mortality [23].
However, in our study, detailed visual field examina-
tion could not be carried out in every child receiving
Vigabatrin because of financial constraints. This may
have lead to underestimation of the side effects of Viga-
batrin. Recent reports have established that eye changes
occur in patients treated with vigabatrin. A prospective
study reports that most children with epileptic syn-
dromes on vigabatrin cannot complain of their eye pro-
blems, hence 3-6 monthly ophthalmic follow up is
strongly advised, along with regular electroretinography,
electro-oculography, and visual evoked potentials if pos-
sible [33]. A study from Oman reports one death in a
patient on vigabatrin therapy due to aspiration pneumo-
nia [34]. Currently, the benefits of treating infantile
spasms with vigabatrin monotherapy seem to outweigh
the risks, but further prospective studies and follow-up
of children receiving treatment are needed to evaluate
the place of vigabatrin in this indication [35]. It is con-
cluded that side effects, even severe ones, are more
common during treatment than had been assumed.
Careful watch is important before and after treatment.
The benefit of very high dosages should also be recon-
sidered [32]. The side effect profile of vigabatrin dictates
that children be started on therapy with a concomitant
short admission to the hospital for better observation
and institution of aspiration precautions. This, however,
has important implications for a developing country like
Pakistan where scarce resources are expended on child
health care.
Four patients in our study developed Lennox Gastaut
Syndrome (LGS) while on therapy. All of these patients
had received Vigabatrin initially and had then been put
on ACTH. A study from Finland reports 27% of patient
with infantile spasms eventually evolving to LGS [36,37].
A review article reported that 20% of all patients with
LGS have prior infantile spasms with hypsarrythmia
[38]. LGS seizures are often treatment resistant and the
long term prognosis is poor [28]. However, we did not
come across any study that reports the association of
children with infantile spasms on a particular therapy
subsequently evolving to LGS.
During 2006 - 2008, we had treated two patients of
infantile spasms with prednisolone at a dose of 1.5 mg/
kg/day. Although this dose of prednisolone was lower
than that used in UKISS study (4 mg/kg/day), it resulted
in resolution of spasms. While the demonstration of this
Ibrahim et al. BMC Pediatrics 2010, 10:1
http://www.biomedcentral.com/1471-2431/10/1
Page 7 of 9aspect with such small numbers is insufficient for analy-
sis or derivation of conclusions, it may be studied
further in the future for better validation.
Strengths and limitations
Literature on pediatric neurology is generally under-
represented from the developing countries. In particular,
studies on experience with ACTH and Vigabatrin in the
treatment of infantile spasms are lacking. Therefore, this
study is an important perspective on the management of
infantile spasms in the setting of a developing country.
To the best of our knowledge, this is the first study of
its kind in Pakistan to compare Vigabatrin and ACTH
as treatment options for infantile spasms.
However, we acknowledge the following limitations of
o u rs t u d y .C o n c l u s i o n sd e r i v e df r o mi ts h o u l db ei n t e r -
preted with these limitations in mind. The study was
based on review of patient charts. Our source of data
was restricted to hospital records which in turn were
reflecting an objective assessment by the physician as
well as reliance on parental descriptions for accounts of
spasms and seizures. These may not be bias free or
accurately recalled in every instance. Secondly, the elec-
tion of treatment was based on several factors such as
availability, cost and ease of administration. The groups
were, however, not randomized. As a result, twice as
many patients received Vigabatrin as compared to
ACTH. All patients didn’t get serial EEGs done. In par-
ticular, control EEGs were not available for all patients
during follow-up. We had divided the groups into symp-
tomatic, cryptogenic and idiopathic. Patients who were
suspected of being symptomatic but for whom an
underlying structural or biochemical cause could not be
identified were classified as cryptogenic. Although
patients were evaluated clinically and radiologically
while such categorization was done, MRI scans were not
performed in all patients due to financial constraints
and CT scans were used in some patients as a less
expensive alternative. MRI studies are important for
defining the cryptogenic groups further.
Conclusion
Vigabatrin was found to be more efficacious in the
treatment of the symptomatic and the idiopathic type of
infantile spasm. However, Vigabatrin and ACTH showed
no significant difference in the initial treatment of infan-
tile spasms. These results are consistent with the find-
ings stated in the practice parameter published in 2004
in Neurology by the American academy of Neurology
(AAN) and Child Neurology Society that bases its
recommendations for the treatment of infantile spasms
on two large surveys conducted in the US and Japan
[25]. Patients receiving ACTH were 1.2 times more
likely to relapse as compared to the patients receiving
Vigabatrin when considering monotherapy. Younger age
at diagnosis of infantile spasms portends resolution of
seizures as compared to older age. Larger studies are
required to validate the therapeutic trends observed in
our study. Birth asphyxia, a potentially preventable con-
dition, was a leading etiology of symptomatic infantile
spasms in our study. We need to gear efforts towards
reducing the incidence of birth asphyxia in our part of
the world through carefully tailored strategies. This will
have an enormous impact by reducing a preventable
cause of symptomatic infantile spasms. Despite all the
advances in understanding the various treatment options
available, infantile spasms still remains an elusive child-
hood disease that is difficult to treat with the overall
prognosis being dismal. The search for an ideal drug
therefore continues - a drug that is not only effective in
controlling spasms, has minimal side effects and
improves long term outcome, but is also easily accessi-
ble to most patients [6].
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